ArticleOncotarget2016
CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Cyclopiane Suppresses Gastric Cancer Invasion and Angiogenesis via the CYR61/αvβ3 Integrin/NF-κB Pathway.Cancer medicine · 2026Article
- Geranylgeranylation signaling promotes breast cancer cell mitosis via the YAP-activated transcription of kinetochore/centromere genes.American journal of cancer research · 2022Article
- Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis.Molecular therapy oncolytics · 2021Article
- Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.Bioscience reports · 2021Article
- TAZ ControlsCells · 2020Article
- ASK1 inhibits proliferation and migration of lung cancer cells via inactivating TAZ.American journal of cancer research · 2020Article
- Geranylgeranylation promotes proliferation, migration and invasion of gastric cancer cells through the YAP signaling pathway.American journal of translational research · 2020Article
- Controlling metastatic cancer: the role of phytochemicals in cell signaling.Journal of cancer research and clinical oncology · 2019Review
- Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion.Frontiers in oncology · 2019Article
- The Hippo signaling effector WWTR1 is a metastatic biomarker of gastric cardia adenocarcinoma.Cancer cell international · 2019Article
- Identification of the Transcriptional Networks and the Involvement in Angiotensin II-Induced Injury after CRISPR/Cas9-Mediated Knockdown of Cyr61 in HEK293T Cells.Mediators of inflammation · 2019Article
- Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.Food science and biotechnology · 2018Article
- MicroRNA-185 suppresses pancreatic cell proliferation by targeting transcriptional coactivator with PDZ-binding motif in pancreatic cancer.Experimental and therapeutic medicine · 2018Article
- Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system (Review).Molecular medicine reports · 2018Review
- Differential expression of CCN family members CYR611, CTGF and NOV in gastric cancer and their association with disease progression.Oncology reports · 2016Article
- TAZ promotes cell growth and inhibits Celastrol-induced cell apoptosis.Bioscience reports · 2016Article
- Expression of Shh, Gli1, and Cyr61 in Gastric Cancer Predicts Overall Survival of Patients: A Retrospective Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cardia adenocarcinoma (GCA) is the most aggressive subtype of gastric cancer with a high metastatic rate. In this report, we collected tumor tissue samples from 214 GCA cases and examined expression of CYR61, a target gene product of the Hippo-YAP/TAZ pathway, in the GCA tumors by immunohistochemical (IHC) staining using the tissue microarray assay (TMA). The results have shown that CYR61 is overexpressed in 44% of the GCA tumor samples. Expression of CYR61 is inversely correlated with cumulative survival of GCA patients (p<0.001) and significantly associated only with metastatic pathological categories (with N category, p=0.052; with TNM stage, p=0.001). Furthermore, knockdown of CYR61 in gastric cancer AGS cells impairs the cancer cell migration and invasion, suggesting a driver role of CYR61 in metastasis. Thus, our studies have established CYR61 as a metastatic biomarker for prediction of poor prognosis of GCA and provided a potential molecular target for anti-metastatic therapy of GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.